Optimizing the Selection and Sequencing of Therapy for Patients with Renal Cell Carcinoma

Optimizing the Selection and Sequencing of Therapy for Patients with Renal Cell Carcinoma

Select Day

13-04-2022

Details: 6 videos

01 Dr. Lianos - Introduction and objectives of meeting

01 Dr. Lianos - Introduction and objectives of meeting

02 Dr. Papadopoulos & Dr. Kampletsas - Recent updates in mRCC: How must we integrate clinical data in everyday clinical practice in 1L RCC? How do we define the right treatment for the right patient based on guidelines?

02 Dr. Papadopoulos & Dr. Kampletsas - Recent updates in mRC...

03 Dr. Biziota - Could the latest clinical data be a critical factor to a therapeutic decision for sarcomatoid and papillary subgroups?

03 Dr. Biziota - Could the latest clinical data be a critica...

04 Dr. Kostouros & Dr. Bokas What to do after the 1st line? Which must be the therapeutic selectioncriteria? What is the appropriate 2nd line treatment following single-agent VEGFR-TKI? What is the appropriate 2nd line treatment following IO-IO Combinatio

04 Dr. Kostouros & Dr. Bokas What to do after the 1st line?...

05 Dr. Kaparelou & Dr. Ziogas - AEs associated with therapies (IO Combos-monotherapies) used to treat metastatic renal cancer

05 Dr. Kaparelou & Dr. Ziogas - AEs associated with therapie...

06 Closing Remarks - Discussion all

06 Closing Remarks - Discussion all

livemed white